Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Behrad Gen Pharmed choriogonadotropin alfa versus Ovitrelle in infertile normal responder women undergoing final follicular maturation
IRCT20250315065092N1Phase 3Completed
- Sponsor
- Behrad Gen Pharmed
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant human chorionic gonadotrophin in female infertility (2 arms), sponsored by Behrad Gen Pharmed. Primary endpoint: Number of oocytes retrieved per patient. Started May 2025; status: completed.
02
Drugs
recombinant human chorionic gonadotrophin
03
Conditions
female infertility
Beyond the preview
Go deeper on IRCT20250315065092N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250315065092N1.